Diamyd presents detailed results of European Phase III study
Diamyd Medical AB reports detailed results from the Company’s European Phase III study of the antigen-based diabetes therapy Diamyd®, which, as previously announced, did not meet the primary efficacy endpoint.Today, June 28, at the “American Diabetes Association’s 71st Scientific Sessions” in San Diego, California, USA, lead investigator Dr. Johnny Ludvigsson presents the detailed results of Diamyd Medical’s European Phase III study of the antigen-based diabetes therapy Diamyd®. The study enrolled 334 patients, 10 to 20 years old, who were diagnosed with type 1 diabetes within three